Trade

with

Anacor Pharmaceuticals Inc
(NASDAQ: ANAC)
AdChoices
27.42
+1.77
+6.90%
After Hours :
27.42
0.00
0.00%

Open

25.97

Previous Close

25.65

Volume (Avg)

637.22k (588.64k)

Day's Range

25.72-27.74

52Wk Range

11.34-27.74

Market Cap.

1.15B

Dividend Rate ( Yield )

-

Beta

1.89

Shares Outstanding

42.00M

P/E Ratio (EPS)

17.06 (1.61)

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
92.52M
Operating Margin
537.02
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
-
Ownership

Institutional Ownership

94.69%

Top 10 Institutions

48.57%

Mutual Fund Ownership

30.79%

Float

78.59%

5% / Insider Ownership

2.65%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • Eagle Small Cap Growth Fund

  •  

    1,258,892

  • 2.44

  • 3.00

  • Fidelity® Select Biotechnology Portfolio

  •  

    903,303

  • 0.00

  • 2.15

  • SPDR® S&P Biotech ETF

  •  

    690,632

  • 0.60

  • 1.72

  • Oppenheimer Global Opportunities

  •  

    600,000

  • 315.46

  • 1.43

  • iShares Nasdaq Biotechnology

  •  

    561,333

  • 3.08

  • 1.40

  • Vanguard Total Stock Mkt Idx

  •  

    529,145

  • 2.55

  • 1.26

  • iShares Russell 2000 (AU)

  •  

    518,199

  • -1.01

  • 1.29

  • Harbor Small Cap Growth Fund

  •  

    500,650

  • 37.51

  • 1.19

  • Loomis Sayles Small Cap Growth Fund

  •  

    408,061

  • -2.47

  • 0.97

  • Vanguard Extended Market Index Fund

  •  

    394,238

  • 33.62

  • 0.94

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Wellington Management Company, LLP

  •  

    3,397,773

  • -2.94%

  • 8.11

  • Baker Bros Advisors LLC

  •  

    3,248,043

  • +4.93%

  • 7.75

  • GlaxoSmithKline PLC

  •  

    2,771,374

  • 0.00%

  • 6.62

  • Eagle Asset Management, Inc.

  •  

    1,973,348

  • +40.49%

  • 4.70

  • Palo Alto Investors, LLC

  •  

    1,661,612

  • -47.15%

  • 3.96

  • Westfield Capital Management Company, LP

  •  

    1,659,070

  • +45.72%

  • 3.96

  • VHCP Management, LLC

  •  

    1,545,999

  • 0.00%

  • 3.69

  • Broadfin Capital, LLC

  •  

    1,443,220

  • +44.20%

  • 3.44

  • Kingdon Capital Management LLC

  •  

    1,355,847

  • +11.18%

  • 3.23

  • BlackRock Fund Advisors

  •  

    1,304,235

  • +8.31%

  • 3.11

Company Profile

Sector

Healthcare

Industry

Biotechnology

Type

Slow Growth

Style

Small Core

Anacor Pharmaceuticals Inc was incorporated in Delaware in December 2000 and began business operations in March 2002. It is a biopharmaceutical company engaged in discovering, developing and commercializing novel small-molecule thera...morepeutics derived from its boron chemistry platform. It has discovered, synthesized and developed eight molecules that are currently in development. The Company’s main product candidates include two topically administered dermatologic compounds, tavaborole (formerly referred to as AN2690) and AN2728. Tavaborole is a topical treatment for onychomycosis, a fungal infection of the nail and nail bed. AN2728 is its main topical anti-inflammatory product candidate for the treatment of atopic dermatitis and psoriasis, chronic inflammatory skin diseases that affect millions of peo...moreple. In addition, the Company has three other wholly-owned clinical product candidates; AN2718 and AN2898, which are backup compounds to tavaborole and AN2728, respectively, and AN3365 (formerly referred to as GSK2251052, or GSK '052), an antibiotic for the treatment of infections caused by Gram-negative bacteria, which previously was licensed to GlaxoSmithKline LLC (GSK). It has also discovered three other compounds that it has out-licensed for further development; one is licensed to Eli Lilly and Company (Lilly), for the treatment of an animal health indication; a second compound, AN5568, also referred to as SCYX-7158, is licensed to Drugs for Neglected Diseases initiative (DNDi), for human African trypanosomiasis (HAT, or sleeping sickness); and a third compound is licensed to GSK for tuberculosis (TB). As of February 1, 2014, the company was the owner of record, either solely or with a collaborator, of 23 issued U.S. patents. The Company and its third-party manufacturers are subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of its products to assess its compliance with applicable regulations.lessless

Key People

Mr. Paul L. Berns

Chairman of the Board/Director/President/CEO

Dr. Lucy Shapiro PhD

Co-Founder/Director

Mr. Geoffrey M. Parker

CFO/Chief Accounting Officer/Executive VP

Vincent Ippolito

Executive VP/Other Executive Officer

Keith R. Leonard

Director

Incorporated

2000

Employees

-

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: